Dashboard PDUFA PDUFA History Dilution Watch Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Track ZYME with free AI briefings, catalyst countdowns, and dilution alerts.

ZYME · Zymeworks Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$322.5M Cash on Hand

24.9mo Cash Runway

10.5% Short Interest

$41.07 Analyst Target (14)

Follow ZYME by email Get an email when ZYME pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ZYME, unsubscribe in one click. Privacy

📣 What ZYME Says Is Next

second half of 2026 · “Johnson and Johnson Innovative Medicine (J&J) expect to present Phase 1b clinical data for pasritamig, a first-in-class bispecific antibody against KLK2, in combination with JNJ-9401 in patients with advanced prostate cancer who have progressed after multiple lines of therapy, during the second half of 2026.”
Company press release, Aug 6, 2026 · SEC filing
mid-2027 · Zanidatamab: “The EmpowHER-303 trial is expected to complete patient enrollment in mid-2027 with top-line data expected by the end of 2027 or early 2028.”
Company press release, Aug 6, 2026 · SEC filing
first half of 2027 · Zanidatamab: “In January 2026, Jazz updated enrollment guidance for EmpowHER-303 in which they expect to complete enrollment in the first half of 2027, with a top-line data readout later in 2027 or in early 2028.”
Company press release, Mar 2, 2026 · SEC filing

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

🧪 Trial & FDA Catalysts

Dec 2026 · Phase 1 · Active Trial · A Study of ZW191 in Participants With Solid Tumors
Registry primary completion date, not a results date
Sep 2027 · Phase 1 · Recruiting · A Study of ZW251 in Participants With Advanced Solid Tumors
Registry primary completion date, not a results date

📊 Drug Pipeline

Drug	Indication	Most advanced trial	Status
Zanidatamab (ZW25)	Biliary Tract Neoplasms	Phase 3 · NCT05615818	Recruiting
Tamoxifen	Breast Cancer	Phase 2 · NCT05035836	Recruiting
Anti-MSLN/Anti-CD3 Bispecific Antibody Z	Mesothelin-expressing Advanced Cancers	Phase 1 · NCT06523803	Terminated
Anti-FRalpha Antibody-drug Conjugate ZW1	Advanced Solid Tumors	Phase 1 · NCT06555744	Active not recruiting
Anti-GPC3 Antibody-drug Conjugate ZW251	Hepatocellular Carcinoma	Phase 1 · NCT07164313	Recruiting
Zanidatamab Zovodotin (ZW49)	HER2-expressing Cancers	Phase 1 · NCT03821233	Completed

Also used in these trials (approved or third-party drugs, not ZYME's own candidates): Cisplatin, Trastuzumab, Niraparib, Neratinib, Ivosidenib, Gemcitabine Hydrochloride, Futibatinib, Encorafenib, Binimetinib, Letrozole.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ZYME holds $322.5M in cash and short-term investments (as of Jun 30, 2026) and burns about $38.8M/quarter from operations, an estimated runway of 24.9 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 25 · Moderate

Cash runway 25 months
ATM program on file since Aug 2024 +15
Shelf registration (S-3ASR, May 2024) +10

Recent financing filings on SEC EDGAR:

Aug 11, 2025 · Private placement (8-K Item 3.02) · 8-K
Jun 27, 2025 · Private placement (8-K Item 3.02) · 8-K
Aug 2, 2024 · ATM program, up to $150M · 424B5
May 3, 2024 · ATM program, up to $150M · 424B5
May 2, 2024 · Shelf registration · S-3ASR
Dec 26, 2023 · Private placement (8-K Item 3.02) · 8-K

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ZYME files for a raise →

👥 Who Owns ZYME

Insiders 33.7% Institutions (297 holders) 66.3% Public and other holders 0%

Holder	Type	Shares	% of shares	As of
EcoR1 Capital, LLC Director, 10% owner	Insider	22,970,388	32.37%	2025-11-16
Rubric Capital Management LP	Institution (13G, 5%+)	7,000,000	9.86%	2026-03-31
Blackrock Inc.	Institution (13F)	4,251,030	5.99%	2026-06-30
Perceptive Advisors LLC	Institution (13G, 5%+)	3,974,579	5.60%	2026-04-08
BVF PARTNERS L P/IL	Institution (13G, 5%+)	3,938,641	5.55%	2025-09-30
BVF Inc.	Institution (13F)	3,649,142	5.14%	2026-06-30
Morgan Stanley	Institution (13F)	2,231,260	3.14%	2026-06-30
BNP Paribas Asset Management Holding S.A	Institution (13F)	1,781,116	2.51%	2026-06-30
Vanguard Capital Management LLC	Institution (13F)	1,558,998	2.20%	2026-06-30
Assenagon Asset Management S.A.	Institution (13F)	1,252,027	1.76%	2026-06-30
Nextech Invest, Ltd.	Institution (13F)	1,113,946	1.57%	2026-06-30
Gregory Austin Ciongoli Director · +81,200 options	Insider	493,500	0.70%	2025-08-11

Share count 70,959,241 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-06-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade date	Insider	Transaction	Shares	Price	Owned after
2026-07-06 filed 2026-07-06	Hollywood Mark	Award (A)	939	$22.22	133,852
2026-05-13 filed 2026-05-15	Schneider Paul R	Option award (A)	119,000	–	–
2026-05-13 filed 2026-05-15	Schneider Paul R	Option award (A)	178,000	–	–
2026-04-09 filed 2026-04-10	Schayowitz Adam	Option award (A)	76,000	–	–
2026-04-09 filed 2026-04-10	Schayowitz Adam	Option award (A)	47,000	–	–

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

📅 Past FDA Decisions & Stock Reactions

Date	Drug	Type	Run-up 30d	Decision 1d	After 5d
2026-08-25	Ziihera	NDA	+25.9%	-4.5%	—

Browse all historical PDUFA outcomes →

Get the full ZYME picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ZYME and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z